Press Releases

WuXi Biologics Receives “Best Bioprocessing Excellence” and “Bioprocessing Innovations in Continuous Processing Implementation in China” Awards from IMAPAC

SHANGHAI, February 13, 2018 – WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it had received the 2018 “Best Bioprocessing Excellence in China” and “Bioprocessing Innovations in Continuous Processing Implementation in China” from IMAPAC, a leading consulting firm.

The Asia-Pacific Bioprocessing Excellence Awards aims to celebrate outstanding bioprocessing experts, organizations, and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost and superior quality. WuXi Biologics not only has been recognized for the best and most innovative biopharmaceutical company in China, with the most recent advances in facility design, adoption of revolutionary technologies and retrofitting, but also has received the recognition for the efforts made in the bioprocessing technological space to pioneer next-generation technologies.

WuXi Biologics has been successively granted “Best Bioprocessing Excellence in China” from IMAPAC for recent two years. In 2017, WuXi Biologics has made remarkable progress in continuous processing and manufacturing. In November, it established continuous bioprocess laboratory in order to work together to develop next-generation biopharmaceutical manufacturing technologies. In December, its cGMP biologics manufacturing facility in Wuxi city with 30,000 L bioreactor capacity entered into full operations, among which are two 1,000 L disposable bioreactors for perfusion processes complete in 2016, marking the largest perfusion biologics manufacturing facility in Asia implementing disposable bioreactors at that time. These achievements will significantly advance the international status of China in biopharmaceutical industry.

“We are honored to receive awards from IMAPAC two years in a row,” said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. “We are committed to enabling WuXi Biologics to become the most comprehensive capability and technology platform in the global biologics industry. WuXi Biologics will continue to improve our existing processes and advance our quality and efficiency to benefit patients worldwide.”

About WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is a leading global open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.

Media Contact:

WuXi Biologics

PR@wuxibiologics.com